Brainchild Bio

Brainchild Bio company information, Employees & Contact Information

Explore related pages

Related company profiles:

We are a kids-first, clinical-stage biotechnology company focused on harnessing the power of CAR-T cell technology for tumors n the central nervous system (CNS), prioritizing pediatrics with plans to expand our technology to adult indications. We are building a platform to optimize the application of CAR-T technology in CNS tumors-- prioritizing diffuse intrinsic pontine glioma (DIPG) with plans to expand to other pediatric and adult brain tumors, including brain metastases.

Company Details

Employees
40
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
Brookline.
Looking for a particular Brainchild Bio employee's phone or email?

Brainchild Bio Questions

News

ScaleReady Announces a G-Rex® Grant has been awarded to BrainChild Bio - PR Newswire

ScaleReady Announces a G-Rex® Grant has been awarded to BrainChild Bio PR Newswire

BrainChild Bio's Pediatric Brain Tumor CAR-T BCB-276 Reels in Breakthrough Therapy Designation - CGTLive®

BrainChild Bio's Pediatric Brain Tumor CAR-T BCB-276 Reels in Breakthrough Therapy Designation CGTLive®

FDA Grants Breakthrough Therapy Designation for BrainChild Bio’s B7-H3 CAR T-Cell Therapy for Incurable Pediatric Brain Tumors - Business Wire

FDA Grants Breakthrough Therapy Designation for BrainChild Bio’s B7-H3 CAR T-Cell Therapy for Incurable Pediatric Brain Tumors Business Wire

OmniaBio Inc. and BrainChild Bio Announce Collaboration to Accelerate CAR-T Cell therapy Development in Brain Cancer - PR Newswire Canada

OmniaBio Inc. and BrainChild Bio Announce Collaboration to Accelerate CAR-T Cell therapy Development in Brain Cancer PR Newswire Canada

Seattle Children's launches BrainChild Bio to accelerate CAR T-cell therapies for children with brain tumors - BioInformant

Seattle Children's launches BrainChild Bio to accelerate CAR T-cell therapies for children with brain tumors BioInformant

FDA Grants Regenerative Medicine Advanced Therapy Designation for BrainChild Bio’s B7-H3 CAR T-cell Therapy for Incurable Pediatric Brain Tumors - Business Wire

FDA Grants Regenerative Medicine Advanced Therapy Designation for BrainChild Bio’s B7-H3 CAR T-cell Therapy for Incurable Pediatric Brain Tumors Business Wire

BrainChild Bio, Inc. to Clinically Advance BCB-276, an Autologous B7-H3 Targeting CAR T-cell Therapy for Incurable Pediatric Brain Tumors - Business Wire

BrainChild Bio, Inc. to Clinically Advance BCB-276, an Autologous B7-H3 Targeting CAR T-cell Therapy for Incurable Pediatric Brain Tumors Business Wire

Top Brainchild Bio Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant